Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1306 to 1320 of 2107 results for technology appraisal

  1. Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention (TA182)

    This guidance has been replaced by NICE technology appraisal guidance 317.

    Withdrawn guidance

  2. Etanercept and infliximab for the treatment of psoriatic arthritis (TA104)

    This guidance has been replaced by NICE technology appraisal guidance 199.

    Withdrawn guidance

  3. Ovarian cancer - topotecan (TA28)

    This guidance has been replaced by NICE technology appraisal guidance 91.

    Withdrawn guidance

  4. Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (TA1134)

    Evidence-based recommendations on dupilumab (Dupixent) for treating severe chronic rhinosinusitis with nasal polyps in adults.

    Technology appraisal guidance
    Published
    18 February 2026
    View recommendations

    Sections for TA1134

  5. Risdiplam for treating spinal muscular atrophy (TA755)

    This guidance has been updated and replaced by NICE's technology appraisal guidance on nusinersen and risdiplam for treating spinal muscular atrophy (TA1162).

    Withdrawn guidance

  6. Nusinersen for treating spinal muscular atrophy (TA588)

    This guidance has been updated and replaced by NICE's technology appraisal guidance on nusinersen and risdiplam for treating spinal muscular atrophy (TA1162).

    Withdrawn guidance

  7. Bortezomib for previously untreated mantle cell lymphoma (TA370)

    Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.

    Technology appraisal guidance
    Published
    16 December 2015
    View recommendations

    Sections for TA370

  8. Ovarian cancer - taxanes (TA3)

    This guidance has been replaced by NICE technology appraisal guidance 55. 

    Withdrawn guidance

  9. Ischaemic heart disease - coronary artery stents (TA4)

    This guidance has been replaced by NICE technology appraisal guidance 71. 

    Withdrawn guidance

  10. Laparoscopic surgery for colorectal cancer (TA17)

    This guidance has been replaced by NICE technology appraisal guidance 105. 

    Withdrawn guidance

  11. Glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA12)

    This guidance has been replaced by NICE technology appraisal guidance 47. 

    Withdrawn guidance

  12. Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events (TA90)

    This guideline has been updated and replaced by NICE technology appraisal 210.

    Withdrawn guidance

  13. Omalizumab for severe persistent allergic asthma (TA133)

    This guidance has been replaced by NICE technology appraisal guidance 278.

    Withdrawn guidance

  14. Research recommendations process and methods guide (PMG45)

    This process and methods guide has been developed to help guidance‑producing centres make research recommendations. It describes a step-by-step approach to identifying uncertainties, formulating research recommendations and research questions, prioritising them and communicating them to the NICE Science Policy and Research (SP&R) team, researchers, and funders

  15. Moderately to severely active ulcerative colitis: adalimumab (ESNM6)

    This evidence summary has been replaced by NICE technology appraisal guidance 329.

    Withdrawn advice